Galmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13

TEL AVIV, Israel, March 5, 2018 /PRNewswire/ --

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed? or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramcholtm, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, announced today that it will host a conference call and webcast on Tuesday, March 13^th, 2018, to provide an update on current developments with respect to its clinical programs for Aramcholtm and to discuss financial results for the three months and full year ended December 31, 2017.

Conference Call & Webcast:

Tuesday, March 13^th @ 8:30am Eastern Time

Toll-Free:                              1-800-289-0438
Toll/International:                   1-323-794-2423
Conference ID:                      1228226
Webcast:                              http://public.viavid.com/index.php?id=128520

Replays available through March 27, 2018

Toll-Free:                              1-844-512-2921
Toll/International:                   1-412-317-6671
Replay PIN:                           1228226

About Aramcholtm and Non-alcoholic Steatohepatitis (NASH)

Aramcholtm (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramcholtm's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramcholtm on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramcholtm has been granted Fast Track designation status by the FDA for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.

About Galmed Pharmaceuticals Ltd.

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramcholtm, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramcholtm in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. More information about the ARREST Study may be found on ClinicalTrials.gov identifier: NCT02279524.

SOURCE Galmed Pharmaceuticals Ltd.